Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

Cited by (241)

Items 101–200 of 241

1. Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: From pharmacology to pre-clinical and clinical therapeutics
   Liu, Zhenghong, Ma, Xiaoxuan, Ilyas, Iqra, Zheng, Xueying, Luo, Sihui, Little, Peter J., Kamato, Danielle, Sahebkar, Amirhossein, Wu, Weiming, Weng, Jianping et al. · 2021 · Theranostics
2. A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors
   Sen, Taha, Heerspink, Hiddo J.L. · 2021 · Cell Metabolism
3. 13. Older Adults: <i>Standards of Care in Diabetes—2024</i>
   American Diabetes Association Professional Practice Committee, ElSayed, Nuha A., Aleppo, Grazia, Bannuru, Raveendhara R., Bruemmer, Dennis, Collins, Billy S., Ekhlaspour, Laya, Hilliard, Marisa E., Johnson, Eric L., Khunti, Kamlesh et al. · 2024 · Diabetes Care
4. Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials
   Ghosh-Swaby, Olivia R, Goodman, Shaun G, Leiter, Lawrence A, Cheng, Alice, Connelly, Kim A, Fitchett, David, Jüni, Peter, Farkouh, Michael E, Udell, Jacob A · 2020 · The Lancet Diabetes &amp; Endocrinology
5. Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial
   Bhatt, Deepak L., Eikelboom, John W., Connolly, Stuart J., Steg, P. Gabriel, Anand, Sonia S., Verma, Subodh, Branch, Kelley R.H., Probstfield, Jeffrey, Bosch, Jackie, Shestakovska, Olga et al. · 2020 · Circulation
6. Benefits and harms of intensive glycemic control in patients with type 2 diabetes
   Rodriguez-Gutierrez, René, Gonzalez-Gonzalez, José Gerardo, Zuñiga-Hernandez, Jorge A, McCoy, Rozalina G · 2019 · BMJ
7. Association of metabolic syndrome and chronic kidney disease
   Scurt, Florian G., Ganz, Maximilian J., Herzog, Carolin, Bose, Katrin, Mertens, Peter R., Chatzikyrkou, Christos · 2024 · Obesity Reviews
8. Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update
   Lipscombe, Lorraine, Butalia, Sonia, Dasgupta, Kaberi, Eurich, Dean T., MacCallum, Lori, Shah, Baiju R., Simpson, Scot, Senior, Peter A. · 2020 · Canadian Journal of Diabetes
9. Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study
   Simms-Williams, Nikita, Treves, Nir, Yin, Hui, Lu, Sally, Yu, Oriana, Pradhan, Richeek, Renoux, Christel, Suissa, Samy, Azoulay, Laurent · 2024 · BMJ
10. GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists
    Górriz, José Luis, Soler, María José, Navarro-González, Juan F., García-Carro, Clara, Puchades, María Jesús, D’Marco, Luis, Martínez Castelao, Alberto, Fernández-Fernández, Beatriz, Ortiz, Alberto, Górriz-Zambrano, Carmen et al. · 2020 · Journal of Clinical Medicine
11. Diagnosis and Treatment of Type 2 Diabetes in Adults
    Kalyani, Rita R., Neumiller, Joshua J., Maruthur, Nisa M., Wexler, Deborah J. · 2025 · JAMA
12. GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: a systematic review and meta-analysis
    Karagiannis, Thomas, Tsapas, Apostolos, Athanasiadou, Eleni, Avgerinos, Ioannis, Liakos, Aris, Matthews, David R., Bekiari, Eleni · 2021 · Diabetes Research and Clinical Practice
13. Effects of SGLT2 inhibitors and GLP-1 receptor agonists on renin-angiotensin-aldosterone system
    Puglisi, Soraya, Rossini, Alessandro, Poli, Roberta, Dughera, Francesca, Pia, Anna, Terzolo, Massimo, Reimondo, Giuseppe · 2021 · Frontiers in Endocrinology
14. Risk factors and prevention strategies for diabetic ketoacidosis in people with established type 1 diabetes
    Ehrmann, Dominic, Kulzer, Bernhard, Roos, Timm, Haak, Thomas, Al-Khatib, Mohammed, Hermanns, Norbert · 2020 · The Lancet Diabetes &amp; Endocrinology
15. Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization
    Khan, Muhammad Shahzeb, Fonarow, Gregg C., McGuire, Darren K., Hernandez, Adrian F., Vaduganathan, Muthiah, Rosenstock, Julio, Handelsman, Yehuda, Verma, Subodh, Anker, Stefan D., McMurray, John J.V. et al. · 2020 · Circulation
16. Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of <scp>SOUL</scp> , a randomized trial
    McGuire, Darren K., Busui, Rodica P., Deanfield, John, Inzucchi, Silvio E., Mann, Johannes F. E., Marx, Nikolaus, Mulvagh, Sharon L., Poulter, Neil, Engelmann, Mads D. M., Hovingh, G. Kees et al. · 2023 · Diabetes, Obesity and Metabolism
17. SGLT2 inhibitors increase the risk of diabetic ketoacidosis developing in the community and during hospital admission
    Hamblin, Peter S, Wong, Rosemary, Ekinci, Elif I, Fourlanos, Spiros, Shah, Sonali, Jones, Alicia R, Hare, Matthew J L, Calder, Genevieve L, Epa, Dilan Seneviratne, George, Elizabeth M et al. · 2019 · The Journal of Clinical Endocrinology &amp; Metabolism
18. SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation
    Tuttle, Katherine R., Brosius, Frank C., Cavender, Matthew A., Fioretto, Paola, Fowler, Kevin J., Heerspink, Hiddo J.L., Manley, Tom, McGuire, Darren K., Molitch, Mark E., Mottl, Amy K. et al. · 2021 · Diabetes
19. Recommendations for management of diabetes during Ramadan: update 2020, applying the principles of the ADA/EASD consensus
    Ibrahim, Mahmoud, Davies, Melanie J, Ahmad, Ehtasham, Annabi, Firas A, Eckel, Robert H, Ba-Essa, Ebtesam M, El Sayed, Nuha Ali, Hess Fischl, Amy, Houeiss, Pamela, Iraqi, Hinde et al. · 2020 · BMJ Open Diabetes Research &amp; Care
20. Natriuretic effect of two weeks of dapagliflozin treatment in patients with type 2 diabetes and preserved kidney function during standardized sodium intake: results of the DAPASALT Trial
    Scholtes, Rosalie A., Muskiet, Marcel H.A., van Baar, Michiel J.B., Hesp, Anne C., Greasley, Peter J., Karlsson, Cecilia, Hammarstedt, Ann, Arya, Niki, van Raalte, Daniël H., Heerspink, Hiddo J.L. · 2021 · Diabetes Care
21. SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: Balancing benefits and risks
    Taylor, Simeon I, Blau, Jenny E, Rother, Kristina I, Beitelshees, Amber L · 2019 · The Lancet Diabetes &amp; Endocrinology
22. Effect of SGLT2 Inhibitors on the Sympathetic Nervous System and Blood Pressure
    Scheen, André J. · 2019 · Current Cardiology Reports
23. Adoption of New Glucose-Lowering Medications in the U.S.—The Case of SGLT2 Inhibitors: Nationwide Cohort Study
    McCoy, Rozalina G., Dykhoff, Hayley J., Sangaralingham, Lindsey, Ross, Joseph S., Karaca-Mandic, Pinar, Montori, Victor M., Shah, Nilay D. · 2019 · Diabetes Technology &amp; Therapeutics
24. Personalized type 2 diabetes management: an update on recent advances and recommendations
    Williams, David M, Jones, Hannah, Stephens, Jeffrey W · 2022 · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
25. Microvascular and cardiovascular outcomes according to renal function in patients treated with once-weekly exenatide: insights from the EXSCEL trial
    Bethel, M. Angelyn, Mentz, Robert J., Merrill, Peter, Buse, John B., Chan, Juliana C., Goodman, Shaun G., Iqbal, Nayyar, Jakuboniene, Neli, Katona, Brian, Lokhnygina, Yuliya et al. · 2020 · Diabetes Care
26. Effects of liraglutide on cardiovascular outcomes in patients with diabetes with or without heart failure
    Marso, Steven P., Baeres, Florian M.M., Bain, Stephen C., Goldman, Bryan, Husain, Mansoor, Nauck, Michael A., Poulter, Neil R., Pratley, Richard E., Thomsen, Anne Bloch, Buse, John B. · 2020 · Journal of the American College of Cardiology
27. Cardiometabolic-Based Chronic Disease, Addressing Knowledge and Clinical Practice Gaps
    Mechanick, Jeffrey I., Farkouh, Michael E., Newman, Jonathan D., Garvey, W. Timothy · 2020 · Journal of the American College of Cardiology
28. Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial
    Ye, Nan, Jardine, Meg J., Oshima, Megumi, Hockham, Carinna, Heerspink, Hiddo J.L., Agarwal, Rajiv, Bakris, George, Schutte, Aletta E., Arnott, Clare, Chang, Tara I. et al. · 2021 · Circulation
29. The effect of dapagliflozin on albuminuria in DECLARE-TIMI 58
    Mosenzon, Ofri, Wiviott, Stephen D., Heerspink, Hiddo J.L., Dwyer, Jamie P., Cahn, Avivit, Goodrich, Erica L., Rozenberg, Aliza, Schechter, Meir, Yanuv, Ilan, Murphy, Sabina A. et al. · 2021 · Diabetes Care
30. Gender difference in cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in type 2 diabetes: a systematic review and meta-analysis of cardio-vascular outcome trials
    Singh, Awadhesh Kumar, Singh, Ritu · 2020 · Diabetes &amp; Metabolic Syndrome: Clinical Research &amp; Reviews
31. Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists through effects on mitochondrial function and oxidative stress
    Luna-Marco, Clara, Iannantuoni, Francesca, Hermo-Argibay, Alberto, Devos, Deédeni, Salazar, Juan D., Víctor, Víctor M., Rovira-Llopis, Susana · 2024 · Free Radical Biology and Medicine
32. Effects of SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysis.
    Tsai, Wen-Hsuan, Chuang, Shih-Ming, Liu, Sung-Chen, Lee, Chun-Chuan, Chien, Ming-Nan, Leung, Ching-Hsiang, Liu, Shu-Jung, Shih, Hong-Mou · 2021 · Scientific Reports
33. Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial
    The EMPA-KIDNEY Collaborative Group, Herrington, William G, Wanner, Christoph, Green, Jennifer B, Hauske, Sibylle J, Judge, Parminder, Mayne, Kaitlin J, Ng, Sarah Y A, Sammons, Emily, Zhu, Doreen et al. · 2022 · Nephrology Dialysis Transplantation
34. Pharmacologic Approaches to Glycemic Treatment of Type 2 Diabetes: Synopsis of the 2020 American Diabetes Association's Standards of Medical Care in Diabetes Clinical Guideline
    Doyle-Delgado, Kacie, Chamberlain, James J., Shubrook, Jay H., Skolnik, Neil, Trujillo, Jennifer · 2020 · Annals of Internal Medicine
35. Effects of the sodium-glucose co-transporter-2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes
    Dekkers, Claire C. J., Sjöström, C. David, Greasley, Peter J., Cain, Valerie, Boulton, David W., Heerspink, Hiddo J. L. · 2019 · Diabetes, Obesity and Metabolism
36. The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials
    Lin, Donna Shu-Han, Lee, Jen-Kuang, Hung, Chi-Sheng, Chen, Wen-Jone · 2021 · Diabetologia
37. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026
    American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, Mandeep, McCoy, Rozalina G., Balapattabi, Kirthikaa, Bannuru, Raveendhara R., Bellini, Natalie J., Bennett, Allison K., Beverly, Elizabeth A., Briggs Early, Kathaleen, ChallaSivaKanaka, Sathyavathi et al. · 2026 · Diabetes Care
38. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026
    American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, Mandeep, McCoy, Rozalina G., Balapattabi, Kirthikaa, Bannuru, Raveendhara R., Bellini, Natalie J., Bennett, Allison K., Beverly, Elizabeth A., Briggs Early, Kathaleen, ChallaSivaKanaka, Sathyavathi et al. · 2026 · Diabetes Care
39. Sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists and the risk for cardiovascular outcomes in routine care patients with diabetes across categories of cardiovascular disease
    Patorno, Elisabetta, Htoo, Phyo T., Glynn, Robert J., Schneeweiss, Sebastian, Wexler, Deborah J., Pawar, Ajinkya, Bessette, Lily G., Chin, Kristyn, Everett, Brendan M., Kim, Seoyoung C. · 2021 · Annals of Internal Medicine
40. &lt;p&gt;Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide&lt;/p&gt;
    Simes, Bryce C, MacGregor, Gordon G · 2019 · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
41. A safety update on sodium glucose co-transporter 2 inhibitors
    Fitchett, David · 2019 · Diabetes, Obesity and Metabolism
42. Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes
    Kalyani, Rita R. · 2021 · New England Journal of Medicine
43. Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure–Related Outcomes: Insights From the EXSCEL Trial
    Fudim, Marat, White, Jennifer, Pagidipati, Neha J., Lokhnygina, Yuliya, Wainstein, Julio, Murin, Jan, Iqbal, Nayyar, Öhman, Peter, Lopes, Renato D., Reicher, Barry et al. · 2019 · Circulation
44. Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease
    Zhang, Yaofu, Jiang, Li, Wang, Junheng, Wang, Tongxin, Chien, Chieh, Huang, Weijun, Fu, Xiaozhe, Xiao, Yonghua, Fu, Qiang, Wang, Shidong et al. · 2022 · Cardiovascular Diabetology
45. Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial
    Clegg, Lindsay E., Penland, Robert C., Bachina, Srinivas, Boulton, David W., Thuresson, Marcus, Heerspink, Hiddo J. L., Gustavson, Stephanie, Sjöström, C. David, Ruggles, James A., Hernandez, Adrian F. et al. · 2019 · Cardiovascular Diabetology
46. Acute kidney injury with sodium-glucose co-transporter-2 inhibitors: a meta-analysis of cardiovascular outcome trials
    Gilbert, Richard E., Thorpe, Kevin E. · 2019 · Diabetes, Obesity and Metabolism
47. Sodium-glucose cotransporter-2 inhibitors and risk of diabetic ketoacidosis among adults with type 2 diabetes: a systematic review and meta-analysis
    Colacci, Michael, Fralick, John, Odutayo, Ayodele, Fralick, Michael · 2022 · Canadian Journal of Diabetes
48. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibition in Kidney Transplant Recipients with Diabetes Mellitus
    Mahling, Moritz, Schork, Anja, Nadalin, Silvio, Fritsche, Andreas, Heyne, Nils, Guthoff, Martina · 2019 · Kidney and Blood Pressure Research
49. Multifactorial intervention has a significant effect on diabetic kidney disease in patients with type 2 diabetes
    Ueki, Kohjiro, Sasako, Takayoshi, Okazaki, Yukiko, Miyake, Kana, Nangaku, Masaomi, Ohashi, Yasuo, Noda, Mitsuhiko, Kadowaki, Takashi · 2021 · Kidney International
50. Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis
    Seminer, Allie, Mulihano, Alfredi, O’Brien, Clare, Krewer, Finn, Costello, Maria, Judge, Conor, O’Donnell, Martin, Reddin, Catriona · 2025 · JAMA Neurology
51. 13. Older Adults: Standards of Care in Diabetes—2026
    American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, Mandeep, McCoy, Rozalina G., Balapattabi, Kirthikaa, Bannuru, Raveendhara R., Bellini, Natalie J., Bennett, Allison K., Beverly, Elizabeth A., Briggs Early, Kathaleen, ChallaSivaKanaka, Sathyavathi et al. · 2026 · Diabetes Care
52. Management of Obesity in Cardiovascular Practice
    Després, Jean-Pierre, Carpentier, André C., Tchernof, André, Neeland, Ian J., Poirier, Paul · 2021 · Journal of the American College of Cardiology
53. First-Line Therapy for Type 2 Diabetes With Sodium–Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists: A Cost-Effectiveness Study
    Choi, Jin G., Winn, Aaron N., Skandari, M. Reza, Franco, Melissa I., Staab, Erin M., Alexander, Jason, Wan, Wen, Zhu, Mengqi, Huang, Elbert S., Philipson, Louis et al. · 2022 · Annals of Internal Medicine
54. Effects of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes in women versus men
    Rådholm, Karin, Zhou, Zien, Clemens, Kristin, Neal, Bruce, Woodward, Mark · 2020 · Diabetes, Obesity and Metabolism
55. Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Patients With Type 2 Diabetes and Other Risk Factors for Cardiovascular Disease: A Meta-analysis
    Bhattarai, Mukul, Salih, Mohsin, Regmi, Manjari, Al-Akchar, Mohammad, Deshpande, Radhika, Niaz, Zurain, Kulkarni, Abhishek, Siddique, Momin, Hegde, Shruti · 2022 · JAMA Network Open
56. Sodium-glucose co-transporter-2 (SGLT-2) inhibitors and cancer: A meta-analysis of randomized controlled trials
    Dicembrini, Ilaria, Nreu, Besmir, Mannucci, Edoardo, Monami, Matteo · 2019 · Diabetes, Obesity and Metabolism
57. Mechanistic insights regarding the role of SGLT2 inhibitors and GLP1 agonist drugs on cardiovascular disease in diabetes
    Garg, Vinay, Verma, Subodh, Connelly, Kim · 2019 · Progress in Cardiovascular Diseases
58. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity
    Gallwitz, Baptist · 2022 · Frontiers in Endocrinology
59. Major adverse cardiovascular and limb events in patients with diabetes treated with GLP-1 receptor agonists vs DPP-4 inhibitors
    Lin, Donna Shu-Han, Lee, Jen-Kuang, Chen, Wen-Jone · 2021 · Diabetologia
60. <scp>Sodium‐glucose co‐transporter‐2</scp> inhibitors with and without metformin: A meta‐analysis of cardiovascular, kidney and mortality outcomes
    Neuen, Brendon L., Arnott, Clare, Perkovic, Vlado, Figtree, Gemma, de Zeeuw, Dick, Fulcher, Greg, Jun, Min, Jardine, Meg J., Zoungas, Sophia, Pollock, Carol et al. · 2021 · Diabetes, Obesity and Metabolism
61. <scp>SGLT2</scp> inhibitor dapagliflozin attenuates cardiac fibrosis and inflammation by reverting the <scp>HIF</scp> ‐2α signaling pathway in arrhythmogenic cardiomyopathy
    Yang, Zhe, Li, Tengling, Xian, Jianzhong, Chen, Jia, Huang, Yin, Zhang, Qin, Lin, Xiufang, Lu, Hongyun, Lin, Yubi · 2022 · The FASEB Journal
62. Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression
    Maiorino, Maria Ida, Longo, Miriam, Scappaticcio, Lorenzo, Bellastella, Giuseppe, Chiodini, Paolo, Esposito, Katherine, Giugliano, Dario · 2021 · Cardiovascular Diabetology
63. Association between sodium–glucose cotransporter-2 inhibitors and risk of sudden cardiac death or ventricular arrhythmias: a meta-analysis of randomized controlled trials
    Sfairopoulos, Dimitrios, Zhang, Nan, Wang, Yueying, Chen, Ziliang, Letsas, Konstantinos P, Tse, Gary, Li, Guangping, Lip, Gregory Y H, Liu, Tong, Korantzopoulos, Panagiotis · 2022 · EP Europace
64. New progress in drugs treatment of diabetic kidney disease
    Wang, Junmin, Xiang, Hongjiao, Lu, Yifei, Wu, Tao, Ji, Guang · 2021 · Biomedicine &amp; Pharmacotherapy
65. Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials
    Staplin, Natalie, Roddick, Alistair J., Emberson, Jonathan, Reith, Christina, Riding, Alex, Wonnacott, Alexa, Kuverji, Apexa, Bhandari, Sunil, Baigent, Colin, Haynes, Richard et al. · 2021 · eClinicalMedicine
66. Sex disparities in cardiovascular outcome trials of populations with diabetes: a systematic review and meta-analysis
    Clemens, Kristin K., Woodward, Mark, Neal, Bruce, Zinman, Bernard · 2020 · Diabetes Care
67. Risk-based primary prevention of heart failure: a scientific statement from the American Heart Association
    Khan, Sadiya S., Breathett, Khadijah, Braun, Lynne T., Chow, Sheryl L., Gupta, Deepak K., Lekavich, Carolyn, Lloyd-Jones, Donald M., Ndumele, Chiadi E., Rodriguez, Carlos J., Allen, Larry A. et al. · 2025 · Circulation
68. Oral semaglutide and cardiovascular outcomes in people with type 2 diabetes, according to SGLT2i use: prespecified analyses of the SOUL randomized trial
    Marx, Nikolaus, Deanfield, John E., Mann, Johannes F.E., Arechavaleta, Rosario, Bain, Stephen C., Bajaj, Harpreet S., Bayer Tanggaard, Katrine, Birkenfeld, Andreas L., Buse, John B., Davicevic-Elez, Zaklina et al. · 2025 · Circulation
69. Relative and absolute risk reductions in cardiovascular and kidney outcomes with canagliflozin across KDIGO risk categories: findings from the CANVAS program
    Neuen, Brendon L., Ohkuma, Toshiaki, Neal, Bruce, Matthews, David R., de Zeeuw, Dick, Mahaffey, Kenneth W., Fulcher, Greg, Blais, Jaime, Li, Qiang, Jardine, Meg J. et al. · 2021 · American Journal of Kidney Diseases
70. Effects of liraglutide compared with placebo on events of acute gallbladder or biliary disease in patients with type 2 diabetes at high risk for cardiovascular events in the LEADER randomized trial.
    Nauck, Michael A., Muus Ghorbani, Marie Louise, Kreiner, Eskil, Saevereid, Hans A., Buse, John B., the LEADER Publication Committee on behalf of the LEADER Trial Investigators · 2019 · Diabetes Care
71. Feasibility of simplification from a basal-bolus insulin regimen to a fixed-ratio formulation of basal insulin plus a glp-1ra or to basal insulin plus an SGLT2 inhibitor: Beyond, a randomized, pragmatic trial
    Giugliano, Dario, Longo, Miriam, Caruso, Paola, Di Fraia, Rosa, Scappaticcio, Lorenzo, Gicchino, Maurizio, Petrizzo, Michela, Bellastella, Giuseppe, Maiorino, Maria Ida, Esposito, Katherine · 2021 · Diabetes Care
72. Effects of dapagliflozin on urinary metabolites in people with type 2 diabetes
    Mulder, Skander, Heerspink, Hiddo J. L., Darshi, Manjula, Kim, Jiwan J., Laverman, Gozewijn D., Sharma, Kumar, Pena, Michelle J. · 2019 · Diabetes, Obesity and Metabolism
73. An evaluation of liraglutide including its efficacy and safety for the treatment of obesity
    Lin, Chen-Hsiu, Shao, Li, Zhang, Yu-Mei, Tu, Yu-Ju, Zhang, Yuzhen, Tomlinson, Brian, Chan, Paul, Liu, Zhongmin · 2020 · Expert Opinion on Pharmacotherapy
74. A systematic review examining the effects of sodium-glucose cotransporter-2 inhibitors (SGLT2is) on biomarkers of inflammation and oxidative stress
    Bray, Jonathan J.H., Foster-Davies, Harri, Stephens, Jeffrey W. · 2020 · Diabetes Research and Clinical Practice
75. Therapy of Type 2 Diabetes
    Landgraf, Rüdiger, Aberle, Jens, Birkenfeld, Andreas L., Gallwitz, Baptist, Kellerer, Monika, Klein, Harald, Müller-Wieland, Dirk, Nauck, Michael A., Reuter, Hans-Martin, Siegel, Erhard · 2019 · Experimental and Clinical Endocrinology &amp; Diabetes
76. DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases
    Handelsman, Yehuda, Anderson, John E., Bakris, George L., Ballantyne, Christie M., Beckman, Joshua A., Bhatt, Deepak L., Bloomgarden, Zachary T., Bozkurt, Biykem, Budoff, Matthew J., Butler, Javed et al. · 2022 · Journal of Diabetes and its Complications
77. Use of Empagliflozin in Recipients of Kidney Transplant: A Report of 8 Cases
    Attallah, Nizar, Yassine, Lina · 2019 · Transplantation Proceedings
78. Assessing the cost-effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus: a comprehensive economic evaluation using clinical trial and real-world evidence
    McEwan, Phil, Bennett, Hayley, Khunti, Kamlesh, Wilding, John, Edmonds, Christopher, Thuresson, Marcus, Wittbrodt, Eric, Fenici, Peter, Kosiborod, Mikhail · 2020 · Diabetes, Obesity and Metabolism
79. Canagliflozin and kidney-related adverse events in type 2 diabetes and CKD: findings from the randomized CREDENCE trial
    Heerspink, Hiddo J.L., Oshima, Megumi, Zhang, Hong, Li, Jingwei, Agarwal, Rajiv, Capuano, George, Charytan, David M., Craig, Jagriti, de Zeeuw, Dick, Di Tanna, Gian Luca et al. · 2022 · American Journal of Kidney Diseases
80. 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome
    Ndumele, Chiadi E., Rodriguez, Fatima, Dixon, Dave L., Khan, Sadiya S., Mukherjee, Debabrata, Bajaj, Mandeep, Bangalore, Sripal, Bozkurt, Biykem, Breathett, Khadijah, Clarke, Shoa L. et al. · 2026 · JACC
81. Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial
    Zelniker, Thomas A., Raz, Itamar, Mosenzon, Ofri, Dwyer, Jamie P., Heerspink, Hiddo H. J. L., Cahn, Avivit, Goodrich, Erica L., Im, Kyungah, Bhatt, Deepak L., Leiter, Lawrence A. et al. · 2021 · JAMA Cardiology
82. Liraglutide as add-on to sodium-glucose co-transporter-2 inhibitors in patients with inadequately controlled type 2 diabetes: lIRA-ADD2SGLT2i, a 26-week, randomized, double-blind, placebo-controlled trial
    Blonde, Lawrence, Belousova, Lidia, Fainberg, Udi, Garcia‐Hernandez, Pedro A., Jain, Sunil M., Kaltoft, Margit S., Mosenzon, Ofri, Nafach, Jalal, Palle, Mads Sundby, Rea, Rosangela · 2020 · Diabetes, Obesity and Metabolism
83. Effects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes: A meta-analysis update
    Salah, Husam M., Al'Aref, Subhi J., Khan, Muhammad Shahzeb, Al-Hawwas, Malek, Vallurupalli, Srikanth, Mehta, Jawahar L., Mounsey, J Paul, Greene, Stephen J., McGuire, Darren K., Lopes, Renato D. et al. · 2021 · American Heart Journal
84. Efficacy and safety profile of SGLT2 inhibitors in the elderly: how is the benefit/risk balance?
    Scheen, André J., Bonnet, Fabrice · 2023 · Diabetes &amp; Metabolism
85. Cost-effectiveness of empagliflozin in patients with diabetic kidney disease in the United States: findings based on the EMPA-REG OUTCOME trial
    Reifsnider, Odette S., Kansal, Anuraag R., Wanner, Christoph, Pfarr, Egon, Koitka-Weber, Audrey, Brand, Sarah B., Stargardter, Matthew, Wang, Cheng, Kuti, Effie, Ustyugova, Anastasia · 2022 · American Journal of Kidney Diseases
86. GLP-1 Receptor Agonists and SGLT2 Inhibitors for the Treatment of Type 2 Diabetes: New Insights and Opportunities for Cardiovascular Protection
    Bertoccini, Laura, Baroni, Marco Giorgio · 2020 · Advances in Experimental Medicine and Biology
87. Sodium–glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes
    Giugliano, Dario, Longo, Miriam, Scappaticcio, Lorenzo, Caruso, Paola, Esposito, Katherine · 2021 · Cardiovascular Diabetology
88. SGLT2 Inhibitors in Liver Patients
    Hsiang, John Chen, Wong, Vincent Wai-Sun · 2020 · Clinical Gastroenterology and Hepatology
89. Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in hyperfiltering people with type 1 diabetes and people with type 2 diabetes and normal kidney function
    van Bommel, Erik J.M., Lytvyn, Yuliya, Perkins, Bruce A., Soleymanlou, Nima, Fagan, Nora M., Koitka-Weber, Audrey, Joles, Jaap A., Cherney, David Z.I., van Raalte, Daniël H. · 2020 · Kidney International
90. Blood pressure-lowering effect of newer antihyperglycemic agents (SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors)
    Liakos, Charalampos I., Papadopoulos, Dimitrios P., Sanidas, Elias A., Markou, Maria I., Hatziagelaki, Erifili E., Grassos, Charalampos A., Velliou, Maria L., Barbetseas, John D. · 2021 · American Journal of Cardiovascular Drugs
91. Relation between HOMA-IR and insulin sensitivity index determined by hyperinsulinemic-euglycemic clamp analysis during treatment with a sodium-glucose cotransporter 2 inhibitor
    So, Anna, Sakaguchi, Kazuhiko, Okada, Yuko, Morita, Yasuko, Yamada, Tomoko, Miura, Hiroshi, Otowa-Suematsu, Natsu, Nakamura, Tomoaki, Komada, Hisako, Hirota, Yushi et al. · 2020 · Endocrine Journal
92. Poor adherence and persistence to sodium glucose co‐transporter 2 inhibitors in real‐world settings: Evidence from a systematic review and meta‐analysis
    Ofori‐Asenso, Richard, Sahle, Berhe W., Chin, Ken Lee, Mazidi, Mohsen, Ademi, Zanfina, De Bruin, Marie Louise, Liew, Danny · 2021 · Diabetes/Metabolism Research and Reviews
93. Sodium glucose co-transporter 2 inhibitors and heart failure.
    Ghosh, Raktim K., Ghosh, Gopal Chandra, Gupta, Manasvi, Bandyopadhyay, Dhrubajyoti, Akhtar, Tauseef, Deedwania, Prakash, Lavie, Carl J., Fonarow, Gregg C., Aneja, Ashish · 2019 · The American Journal of Cardiology
94. Real-World Evidence Should Be Used in Regulatory Decisions About New Pharmaceutical and Medical Device Products for Diabetes
    Klonoff, David C., Gutierrez, Alberto, Fleming, Alexander, Kerr, David · 2019 · Journal of Diabetes Science and Technology
95. The interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease
    Finney, Alexandra C., Das, Sandeep, Kumar, Dhananjay, McKinney, M. Peyton, Cai, Bishuang, Yurdagul, Arif, Rom, Oren · 2023 · Frontiers in Cardiovascular Medicine
96. Sodium-glucose cotransporter 2 (SGLT-2) inhibitors and microvascular outcomes in patients with type 2 diabetes: systematic review and meta-analysis
    Dorsey-Treviño, E. G., González-González, J. G., Alvarez-Villalobos, N., González-Nava, V., Contreras-Garza, B. M., Díaz González-Colmenero, A., Rodríguez-Tamez, G., Barrera-Flores, F. J., Farrell, A. M., Montori, V. M. et al. · 2020 · Journal of Endocrinological Investigation
97. Significance of Glycemic Variability in Diabetes Mellitus
    Kusunoki, Yoshiki, Konishi, Kosuke, Tsunoda, Taku, Koyama, Hidenori · 2022 · Internal Medicine
98. Cardiovascular Protection With Sodium-Glucose Cotransporter-2 Inhibitors and Mineralocorticoid Receptor Antagonists in Chronic Kidney Disease: A Milestone Achieved
    Sarafidis, Pantelis, Papadopoulos, Christodoulos E., Kamperidis, Vasilios, Giannakoulas, George, Doumas, Michael · 2021 · Hypertension
99. The renoprotective effects of sodium-glucose cotransporter 2 inhibitors versus placebo in patients with type 2 diabetes with or without prevalent kidney disease: a systematic review and meta-analysis
    Wang, Chen, Zhou, Yue, Kong, Zili, Wang, Xiang, Lv, Wenshan, Geng, Zhuang, Wang, Yangang · 2019 · Diabetes, Obesity and Metabolism
100. An Overview of the Cardioprotective Effects of Novel Antidiabetic Classes: Focus on Inflammation, Oxidative Stress, and Fibrosis
     Balogh, Dora Bianka, Wagner, Laszlo Jozsef, Fekete, Andrea · 2023 · International Journal of Molecular Sciences